**Supplemental Table 3: Summary of clinical characteristics, complications, and laboratory values separated by thrombotic events and ECMO requirement**

|  |  |  |
| --- | --- | --- |
|   | No ECMO |  ECMO |
|   | No Thrombus | Thrombus | No Thrombus | Thrombus |
| N, total patients | 39 | 7 | 2 | 7 |
| Age, (SD) | 58 (12.0) | 58 (8.2) | 53 (4.5) | 50 (8.9) |
| Female, (%) | 12 (30%) | 0 | 1 (50%) | 1 (14.3%) |
| Male, (%) | 28 (70%) | 7 (100%) | 1 (50%) | 6 (85.7%) |
| PiO2/FiO2,a (SD) | 183 (85.7) | 144 (42.6) | 127 (25.8) | 173 (69.0) |
| Ventilator Days, (SD) | 15 (8.3) | 14 (6.1) | 17 (8.0) | 19 (4.5) |
| Major Bleed, (%) | 0 | 2 (28.6%) | 2 (100%) | 5 (71.4%) |
| Major thrombotic events, (%) | 0 | 7 (100%) | 0 | 7 (100%) |
| Ventilator-associated pneumonia, (%) | 14 (35%) | 6 (85.7%) | 2 (100%) | 5 (71.4%) |
| Continuous renal replacement therapy, (%) | 4 (10%) | 2 (28.6%) | 0 | 4 (57.1%) |
| Heart Failure/myocarditis, (%) | 2 (5%) | 0 | 0 | 1 (14.3%) |
| Arrhythmias, (%) | 4 (10%) | 1 (14.3%) | 0 | 1 (14.3%) |
| Death, (%) | 7 (17.5%) | 4 (57.1%) | 1 (50%) | 1 (14.3%) |
|  | No ECMO | ECMO |
| No Thrombus | Thrombus | No Thrombus | Thrombus |
| 90 day Survival, (%) |  33 (82.5%) | 3 (42.8%) | 1 (50%) | 6 (85.7%) |
| Aspartate Transaminase, U/L (SD) | 60 (116) | 76 (66) | 42 (24) | 52 (26) |
| Alanine Aminotransferase, U/L (SD) | 44 (54) | 44 (24) | 24 (9) | 45 (20) |
| D-Dimer, ng/mL (SD) | 4982 (12116) | 7787 (8938) | 8043 (13498) | 29670 (27044) |
| Hematocrit, % (SD) | 30 (5) | 27 (6) | 25 (4) | 25 (3) |
| Platelets, x109/L (SD) | 311 (100) | 294 (194) | 125 (43) | 177 (77) |
| White Blood Count, x103/mL (SD) | 11.1 (4.3) | 14.0 (9.4) | 12.4 (3.6) | 14.4 (5.0) |
| C-Reactive Protein, mg/L (SD) | 6.8 (6.7) | 17.1 (7.3) | 13.7 (13.4) | 15.8 (5.2) |
| Fibrinogen, mg/dL (SD) | 522 (235) | 531 (261) | 361 (204) | 452 (190) |
| Lactate, mmol/L (SD) | 1.91 (0.89) | 3.34 (1.86) | 1.70 (0.14) | 1.01 (0.33) |
| Lactate Dehydrogenase, U/L (SD) | 305 (182) | 441 (154) | 423(105) | 424 (127) |
| pH, (SD) | 7.39 (0.07) | 7.32 (0.13) | 7.36 (0.06) | 7.37 (0.06) |
| INR, (SD) | 1.13 (0.08) | 1.76 (0.73) | 1.2 (0.07) | 1.01 (0.08) |
| PTT, seconds (SD) | 42.7 (40.1) | 62.5 (44.4) | 40.8 (9.5) | 41.5 (11.9) |
|  | No ECMO | ECMO |
|  | No Thrombus | Thrombus | No Thrombus | Thrombus |
| Creatinine, mg/dL (SD) | 1.79 (1.53) | 1.48 (0.90) | 0.84 (0.42) | 1.94 (1.34) |
| Von Willebrand Factor, µg/mL (SD) | 40.7 (23.4) | 48.7 (24.3) | 33.1 (15.4) | 41.6 (15.6) |
| A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, ng/mL (SD) | 486 (181) | 399 (127) | 118 (25) | 307 (104) |
| Plasminogen activator inhibitor-1, ng/mL (SD) | 27.1 (18.3) | 38.1 (16.2) | 18.1 (6.9) | 39.5 (16.3) |
| Tissue factor pathway inhibitor, ng/mL (SD) | 349 (132) | 538 (245) | 496 (171) | 519 (144) |
| Microparticle-bound tissue factor, pg/mL (SD) | 1.0 (0.7) | 2.4 (1.6) | 1.0 (0.3) | 1.1 (0.7) |
| Factor VIII activity, Opital Density at 650 nm (SD) | 1.39 (0.23) | 1.51 (0.20) | 0.91 (0.29) | 1.32 (0.36) |
| Anti-Factor Xa activity, IU/mL (SD) | 0.13 (0.09) | 0.22 (0.09) | 0.16 (0.07) | 0.12 (0.05) |